Determinants of acute regional toxicity following isolated limb perfusion for melanoma

Melanoma Research

Volumn 6, Issue 3, 1996, Pages 267-271

  Thompson, J F ^a,b   Eksborg, S ^c   Kam, P C A ^a,b   Ingvar, C ^d   Yau, D F ^a   Lai, D T M ^a   Ramzan, I ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Isolated limb; Melanoma; Melphalan; Perfusion; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; DACTINOMYCIN; MELPHALAN;

AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG UPTAKE; ERYTHEMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTHERMIA; LIMB PERFUSION; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; RECURRENT CANCER; TISSUE INJURY;

ANTINEOPLASTIC AGENTS, ALKYLATING; ARM; BODY TEMPERATURE; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LEG; MELANOMA; MELPHALAN; METABOLIC CLEARANCE RATE; TOURNIQUETS;

EID: 0029957851     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199606000-00010     Document Type: Article

References (24)

1. Schraffordt Koops H, Kroon BBR, Lejeune FJ. Isolated regional perfusion in the treatment of local recurrence, satellites and in-transit metastases of extremity melanomas. In. Rumke P, ed. Therapy of Advanced Melanoma: Pigment Cell. Basel: Karger, 1990: 67-78.
2. Krementz ET, Ryan RF, Muchmore, JH, Carter RD, Sutherland CM, Reed RJ. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, eds. Cutaneous Melanoma, 2nd edn. Philadelphia: Lippincott, 1992: 403-426.
3. Kroon BBR. Regional isolated limb perfusion in melanoma of the limbs: accomplishments, unresolved problems, future. Eur J Surg Oncol 1988; 14: 101-110.
4. Thompson JF, Good PD, Kam PCA. Hyperthermic isolated limb perfusion in the treatment of melanoma: technical aspects. Reg Cancer Treat (1994); 7: 147-154.
5. Van Geel AN, van Wijk J, Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer 1989; 68: 1092-1095.
6. Olieman AF, Schrafford-Koops HS, Geertzen JH et al. Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol 1994; 1: 382-388.
7. Wieberdink KJ, Benckhuijsen C, Braat RP et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910.
8. Lejeune FJ, Vaglini M, Schraffordt-Koops H et al. A randomised trial on prophylactic isolation perfusion for Stage I high risk (i.e. > 1.5 mm thickness) malignant melanoma of the limbs: an interim report. Melanoma Res 1993, 3: 95.
9. Chang SY, Alberts DS, Farquar D et al. Hydrolysis and protein binding of melphalan. J Pharm Sci 1978; 67: 682-684.
10. Gibaldi M, Perrier D. Multicompartmental models. In: Pharmacokinetics. New York: Marcel Dekker Inc., 1982: 45-111.
11. Thompson JF, Kam PCA, Ramzan I. and Yau DF. Clinical pharmacokinetics of melphalan in isolated limb perfusion: compartmental modelling and moment analysis. Reg Cancer Treat (1995); 8: 83-87.
12. Klasse, JM, Kroon BBR, Van Geel BN, et al. Patient and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surgery 1994; 167: 618-620.
13. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227-233.
14. Lienard D, Lejeune F, Autier P et al. Physiological and pharmacokinetic parameters in isolation perfusion of the limbs. In: Lejeune F, Chaudhuri PK and Das Gupta TK, eds. Malignant Melanoma-medical and surgical management. New York: McGraw-Hill, 1994: 241-248.
15. Cavaliere R, Ciocatto RC, Giovanella BC et al. Selective heat sensitivity of cancer cells: biochemical and clinical studies. Cancer 1967; 20: 1351-1381.
16. Stehlin JS, Giovenella B, De Ipolyi PD et al. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975; 140: 339-348.
17. Klaase JM, Kroon BBR, Beijnen JH et al. Melphalan tissue concentration in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 1994; 70: 151-153.
18. Benckhuijsen C, Varossieau FJ, Hart AAM et al. Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther 1986; 237: 583-588.
19. Lai DTM, Ingvar C, Thompson JF. The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat 1993; 1: 36-39.
20. Thompson JF, Lai DTM, Ingvar C, Kam PCA. Maximizing efficacy and minimizing toxicity in isolated limb perfusion. Melanoma Res 1994; 4: 45-50.
21. Lai DTM, Ingvar C, Kam PCA, Thompson JF. Drug dosage calculation for isolated limb perfusion by perfusion circuit volume measurements using indocyanine green. Melanoma Res 1993; 3: 91.
22. Scott RN, Kerr DJ, Blackie R et al. The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer 1992; 66: 159-166.
23. Stotter AT, Robinson B, Clutterbuck R et al. A companion of melphalan levels achieved in isolated limb infusion and systemic high dose therapy. J Exp Clin Cancer Res 1987; 6: 161-165.
24. Scott RN, Blackie R, Kerr DJ et al. Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 1992; 28: 1811-1813.